Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Apr 7, 2014; 20(13): 3609-3614
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3609
Published online Apr 7, 2014. doi: 10.3748/wjg.v20.i13.3609
Association of rs1568885, rs1813443 and rs4411591 polymorphisms with anti-TNF medication response in Greek patients with Crohn’s disease
Diamantis Thomas, Theodoros Karantanos, Konstantinos Bramis, George Zografos, George E Theodoropoulos, Colorectal Unit, 1st Department of Propaedeutic Surgery, “Hippokrateio” Hospital, School of Medicine, University of Athens, 11527 Athens, Greece
Maria Gazouli, Stella Rigoglou, Department of Basic Medical Science, Laboratory of Biology, School of Medicine, University of Athens, 11527 Athens, Greece
Georgios Karamanolis, Gastroenterology Unit, 2nd Department of Surgery, “Aretaieio” Hospital, University of Athens, Athens 11527, Greece
Author contributions: All authors contributed to the manuscript.
Correspondence to: Maria Gazouli, Assistant Professor, Department of Basic Medical Science, Laboratory of Biology, School of Medicine, University of Athens, Michalakopoulou 176, 11527 Athens, Greece. mgazouli@med.uoa.gr
Telephone: +30-210-7462231 Fax: +30-210-7462231
Received: November 19, 2013
Revised: December 23, 2013
Accepted: January 20, 2014
Published online: April 7, 2014
Processing time: 136 Days and 12.4 Hours
Revised: December 23, 2013
Accepted: January 20, 2014
Published online: April 7, 2014
Processing time: 136 Days and 12.4 Hours
Core Tip
Core tip: A common treatment for inflammatory bowel disease is the use of tumor necrosis factor (TNF)-α inhibitors such as Infliximab (IFX). The discovery of novel markers of response to anti-TNF agents will provide valuable information for better stratification of these patients which will eventually further improve their clinical course and quality of life. Our results suggest that the rs1568885 and rs1813443 polymorphisms are associated with clinical and biochemical response to IFX in patients with Crohn’s disease.